The European Investment Bank (EIB) agreed a €30 million loan with Vakzine Projekt Management GmbH (VPM). This loan will help VPM to perform the priMe trial. The priMe project contains a multicentre phase III double-blind, randomised, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG. Vaccine research and development for the project will be carried out by VPM and the clinical trials will be scaled up in several high-burden sub-Saharan countries.
For more information, please read the Press_Release
